2,4,6-trichlorobenzimidazole | 142356-47-6

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 2,4,6-trichlorobenzimidazole
• 英文别名: 2,4,6-trichloro-1H-benzimidazole
• CAS: 142356-47-6
• 化学式: C₇H₃Cl₃N₂
• 分子量: 221.473
• InChiKey: BOSXUUUAOBZQGK-UHFFFAOYSA-N

物化性质

• 沸点：
  396.0±45.0 °C(Predicted)
• 密度：
  1.691±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2,4,6-trichlorobenzimidazole 在 三氯化硼 、 sodium hydride 作用下， 以 二氯甲烷 为溶剂， 反应 24.33h， 生成 2-[(2,4,6-Trichlorobenzimidazol-1-yl)methoxy]propane-1,3-diol
  参考文献：
  名称：

  2-取代的5,6-二氯-，4,6-二氯-和4,5-二氯-1-[（2-羟基乙氧基）甲基]-和-1-[（1,3-）之间的结构活性关系二羟基-2-丙氧基）甲基]苯并咪唑。

  摘要：

  2,5,6-三氯苯并咪唑的钠盐（8a）与[2-（苄氧基）乙氧基]-甲基氯（9）和[1,3-双（苄氧基）-2-丙氧基]甲基氯（18 ）以提供相应的被保护的无环核苷10a和19a，它们在脱苄基作用后得到2,5,6-三氯-1-[（2-羟基乙氧基）甲基]苯并咪唑（11a）和2,5,6-三氯-1- [ （1，3-二羟基-2-丙氧基）甲基]苯并咪唑（20a）。2,4,6-三氯苯并咪唑（2a）和2,4,5-三氯苯并咪唑（7a）的类似缩合，然后进行脱苄基作用，分别得到11b，20b，11c和20c。用液态氨，甲胺，二甲胺和硫脲对11a-c和20a-c的2-氯基进行亲核取代，以高收率提供了几种有趣的2-取代化合物，例如12-14（ae），21-23 （ae），15-17和24-26。2-硫代类似物15-17和24-26与苄基氯的烷基化提供了2-烷硫基无环核苷12d-14d和21d-23d。用阮内镍将15和24脱硫，得到5

  DOI：

  10.1021/jm950556a
• 作为产物：
  描述：

  4,6-Dichlor-benzimidazolon 在 N,N-二甲基苯胺 、 三氯氧磷 作用下， 生成 2,4,6-trichlorobenzimidazole
  参考文献：
  名称：

  Design, syntheses, and structure–activity relationships of novel NPY Y5 receptor antagonists: 2-{3-Oxospiro[isobenzofuran-1(3H),4′-piperidin]-1′-yl}benzimidazole derivatives

  摘要：

  Design, syntheses, and structure-activity relationships of a novel class of 2-{3-oxospiro[isobenzofuran-1(3H),4'-piperidin]-1'-yl}benzimidazole NPY Y5 receptor antagonists are described. The benzimidazole structures were newly designed based on the urea linkage of our prototype Y5 receptor antagonists (2 and 3). By optimizing substituents on the benzimidazole core part of the lead compound 5a, we were able to develop a potent, orally available, and brain-penetrable Y5 selective antagonist (5k). Crown Copyright (C) 2008 Published by Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.08.018

文献信息

• Piperazine derivatives and the use thereof as medicament
  申请人：HOENKE Christoph

  公开号：US20150105397A1

  公开（公告）日：2015-04-16

  The present inventions relate to substituted piperazine derivatives of general formula (I) and to the manufacture of said compounds, pharmaceutical compositions comprising a compound according to general formula (I), and the use of said compounds for the treatment of various medical conditions related to glycine transporter-1 (GlyT1).

  这些发明涉及一般式(I)的取代哌嗪衍生物，以及所述化合物的制备，包括符合一般式(I)的化合物的药物组合物，以及利用这些化合物治疗与甘氨酸转运蛋白-1（GlyT1）相关的各种医疗状况。
• Polysubstituted benzimidazole nucleosides as antiviral agents
  申请人：The Regents of the University of Michigan

  公开号：US05248672A1

  公开（公告）日：1993-09-28

  This invention relates to novel polysubstituted benzimidazole nucleosides and compositions and their use in the treatment of viral infections, particulary those caused by human cytomegalovirus and herpes simplex virus. Such substituted compounds exhibit antiviral properties superior to their parent compounds and low leve SPONSORSHIP This invention was made with government support under Contract No. NO1 Al 42554 and NO1 Al 72641 awarded by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health. The government has certain rights in this invention.

  本发明涉及新型多取代苯并咪唑核苷及其组合物，以及它们在治疗病毒感染中的应用，特别是人类巨细胞病毒和单纯疱疹病毒引起的感染。这些取代化合物表现出比它们的原始化合物更优异的抗病毒性能和低水平的赞助。本发明是在国家卫生研究院过敏与传染病国家研究所授予的合同号NO1 Al 42554和NO1 Al 72641的政府支持下完成的。政府对本发明享有某些权利。
• Design, Synthesis, and Antiviral Evaluation of 2-Substituted 4,5-Dichloro- and 4,6-Dichloro-1-β-<scp>d</scp>-ribofuranosylbenzimidazoles as Potential Agents for Human Cytomegalovirus Infections
  作者：Ruiming Zou、John C. Drach、Leroy B. Townsend

  DOI：10.1021/jm960533b

  日期：1997.2.1

  (14a), and 2-benzylthio (14b) derivatives were prepared via displacement reactions at the 2-position of the 2,3,5-tri-O-acetyl derivative of 7a. 2,4,5-Trichlorobenzimidazole (17a) and 2-bromo-4,5-dichlorobenzimidazole (17b) were synthesized from the corresponding 1,2-phenylenediamines via successive cyclization with cyanogen bromide and diazotization in the presence of an appropriate cupric halide. Ribosylation

  2,4-，6-三氯苯并咪唑（4a）和2-溴-4,6-二氯苯并咪唑（4b）的合成通过2-氨基中间体（3）使用温和的重氮化程序完成。4a和4b的核糖基化反应以及随后的脱保护得到相应的2,4,6-三氯-1-β-D-核呋喃糖基苯并咪唑（7a）和2-溴-4,6-二氯-1-β-D-核呋喃糖基苯并咪唑（7b） 。通过在2的2位上进行置换反应制备了2-叠氮基（10），2-氨基（11），2-硫酮（13），2-甲硫基（14a）和2-苄硫基（14b）衍生物。 7a的，3，5-三-O-乙酰基衍生物。由相应的1,2-苯二胺经溴化氰连续环化并在适当的卤化铜存在下重氮化，从而合成了2,4,5-三氯苯并咪唑（17a）和2-溴-4,5-二氯苯并咪唑（17b）。化合物17a和17b的核糖基化反应后，脱保护得到2,4,5-三氯-1-β-D-呋喃呋喃糖基苯并咪唑（20a）和2-溴-4,5-二氯-1-β-D-呋喃呋喃糖基苯并咪唑（
• Polysubstituted benzimidazoles as antiviral agents
  申请人：The Regents of the University of Michigan

  公开号：US05646125A1

  公开（公告）日：1997-07-08

  This invention relates to novel polysubstituted benzimidazoles and compositions and their use in the treatment of viral infections. The polysubstituted benzimidazoles and compositions of the present invention exhibit antiviral properties against viruses of the herpes family, particularly human cytomegalovirus (HCMV) and herpes simplex viruses (HSV).

  本发明涉及新型多取代苯并咪唑及其组合物，以及它们在治疗病毒感染方面的应用。本发明的多取代苯并咪唑和组合物对疱疹病毒家族的病毒，尤其是人类巨细胞病毒（HCMV）和单纯疱疹病毒（HSV）表现出抗病毒特性。
• Treatment of herpes infections with polysubstituted benzimidazoles
  申请人：The Regents of the University of Michigan

  公开号：US05712255A1

  公开（公告）日：1998-01-27

  A method for treating a herpes viral infection comprising administering to the infected host a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt or formulation thereof, selected from the group consisting of compounds having the following formula: ##STR1## wherein: R.sub.1 is H, R.sub.2 is Cl, R.sub.3 is Cl, R.sub.4 is H, R.sub.5 is Br and R.sub.6 is .beta.-D-ribofuranosyl (denoted compound 52 in the text); R.sub.1 is H, R.sub.2 is NO.sub.2, R.sub.3 is NO.sub.2, R.sub.4 is H, R.sub.5 is Cl and R.sub.6 is .beta.-D-ribofuranosyl (denoted compound 61 in the text); R.sub.1 is Cl, R.sub.2 is H, R.sub.3 is Cl, R.sub.4 is H, R.sub.5 is Cl and R.sub.6 is .beta.-D-ribofuranosyl (denoted compound 81 in the text); R.sub.1 is H, R.sub.2 is Cl, R.sub.3 is Cl, R.sub.4 is H, R.sub.5 is I and R.sub.6 is .beta.-D-ribofuranosyl (denoted compound 83a in the text); R.sub.1 is Br, R.sub.2 is Br, R.sub.3 is H, R.sub.4 is H, R.sub.5 is Cl and R.sub.6 is .beta.-D-ribofuranosyl (denoted compound 85 in the text); R.sub.1 is H, R.sub.2 is Br, R.sub.3 is Cl, R.sub.4 is H, R.sub.5 is Cl and R.sub.6 is .beta.-D-ribofuranosyl (denoted compound 95 in the text); R.sub.1 is H, R.sub.2 is Cl, R.sub.3 is Br, R.sub.4 is H, R.sub.5 is Cl and R.sub.6 is .beta.-D-ribofuranosyl (denoted compound 99 in the text); R.sub.1 is H, R.sub.2 is I, R.sub.3 is I, R.sub.4 is H, R.sub.5 is Cl and R.sub.6 is .beta.-D-ribofuranosyl (denoted compound 107 in the text); R.sub.1 is H, R.sub.2 is Cl, R.sub.3 is Cl, R.sub.4 is H, R.sub.5 is Cl and R.sub.6 is 2'-deoxy-.beta.-D-erythro-pentofuranosyl (denoted compound 111 in the text); R.sub.1 is H, R.sub.2 is Cl, R.sub.3 is Cl, R.sub.4 is H, R.sub.5 is Br and R.sub.6 is 2'-deoxy-.beta.-D-erythro-pentofuranosyl (denoted compound 112 in the text); R.sub.1 is Cl, R.sub.2 is Cl, R.sub.3 is Cl, R.sub.4 is Cl, R.sub.5 is Cl and R.sub.6 is (1,3-dihydroxy-2-propoxy)methyl (denoted compound 155 in the text); R.sub.1 is Cl, R.sub.2 is Cl, R.sub.3 is Cl, R.sub.4 is Cl, R.sub.5 is NH.sub.2 and R.sub.6 is (1,3-dihydroxy-2-propoxy)methyl (denoted compound 156 in the text); R.sub.1 is Cl, R.sub.2 is Cl, R.sub.3 is Cl, R.sub.4 is Cl, R.sub.5 is OCH.sub.3 and R.sub.6 is 2-hydroxyethoxymethyl (denoted compound 166a in the text); R.sub.1 is Cl, R.sub.2 is Cl, R.sub.3 is Cl, R.sub.4 is Cl, R.sub.5 is NH.sub.2 and R.sub.6 is 2-hydroxyethoxymethyl (denoted compound 167 in the text); and R.sub.1 is H, R.sub.2 is Cl, R.sub.3 is Cl, R.sub.4 is H, R.sub.5 is NH.sub.2 and R.sub.6 is benzyl (denoted compound 182 in the text).

  一种治疗单纯疱疹病毒感染的方法，包括向受感染宿主投与以下化合物中的一种，或其在药学上可接受的盐或制剂，所述化合物具有以下公式： ##STR1## 其中：R.sub.1为H，R.sub.2为Cl，R.sub.3为Cl，R.sub.4为H，R.sub.5为Br，R.sub.6为β-D-核糖呋喃（在文本中标记为化合物52）；R.sub.1为H，R.sub.2为NO.sub.2，R.sub.3为NO.sub.2，R.sub.4为H，R.sub.5为Cl，R.sub.6为β-D-核糖呋喃（在文本中标记为化合物61）；R.sub.1为Cl，R.sub.2为H，R.sub.3为Cl，R.sub.4为H，R.sub.5为Cl，R.sub.6为β-D-核糖呋喃（在文本中标记为化合物81）；R.sub.1为H，R.sub.2为Cl，R.sub.3为Cl，R.sub.4为H，R.sub.5为I，R.sub.6为β-D-核糖呋喃（在文本中标记为化合物83a）；R.sub.1为Br，R.sub.2为Br，R.sub.3为H，R.sub.4为H，R.sub.5为Cl，R.sub.6为β-D-核糖呋喃（在文本中标记为化合物85）；R.sub.1为H，R.sub.2为Br，R.sub.3为Cl，R.sub.4为H，R.sub.5为Cl，R.sub.6为β-D-核糖呋喃（在文本中标记为化合物95）；R.sub.1为H，R.sub.2为Cl，R.sub.3为Br，R.sub.4为H，R.sub.5为Cl，R.sub.6为β-D-核糖呋喃（在文本中标记为化合物99）；R.sub.1为H，R.sub.2为I，R.sub.3为I，R.sub.4为H，R.sub.5为Cl，R.sub.6为β-D-核糖呋喃（在文本中标记为化合物107）；R.sub.1为H，R.sub.2为Cl，R.sub.3为Cl，R.sub.4为H，R.sub.5为Cl，R.sub.6为2'-脱氧-β-D-erythro-戊呋喃核苷（在文本中标记为化合物111）；R.sub.1为H，R.sub.2为Cl，R.sub.3为Cl，R.sub.4为H，R.sub.5为Br，R.sub.6为2'-脱氧-β-D-erythro-戊呋喃核苷（在文本中标记为化合物112）；R.sub.1为Cl，R.sub.2为Cl，R.sub.3为Cl，R.sub.4为Cl，R.sub.5为Cl，R.sub.6为（1,3-二羟基-2-丙氧基）甲基（在文本中标记为化合物155）；R.sub.1为Cl，R.sub.2为Cl，R.sub.3为Cl，R.sub.4为Cl，R.sub.5为NH.sub.2，R.sub.6为（1,3-二羟基-2-丙氧基）甲基（在文本中标记为化合物156）；R.sub.1为Cl，R.sub.2为Cl，R.sub.3为Cl，R.sub.4为Cl，R.sub.5为OCH.sub.3，R.sub.6为2-羟基乙氧基甲基（在文本中标记为化合物166a）；R.sub.1为Cl，R.sub.2为Cl，R.sub.3为Cl，R.sub.4为Cl，R.sub.5为NH.sub.2，R.sub.6为2-羟基乙氧基甲基（在文本中标记为化合物167）；R.sub.1为H，R.sub.2为Cl，R.sub.3为Cl，R.sub.4为H，R.sub.5为NH.sub.2，R.sub.6为苄基（在文本中标记为化合物182）。